Atenolol Should NOT Be Used for Anxiety Treatment
Based on the most recent and highest-quality guideline evidence, atenolol is explicitly NOT recommended for anxiety disorders and should be avoided. The 2023 Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology clinical practice guideline, citing the Canadian Clinical Practice Guideline, specifically deprecates beta-blockers including atenolol for social anxiety disorder based on negative evidence 1.
Why Atenolol Fails for Anxiety
The guideline evidence is clear: atenolol and propranolol are both deprecated for anxiety treatment 1. This recommendation supersedes older, smaller studies that suggested potential benefit. The Canadian CPG reviewed the totality of evidence and concluded these beta-blockers lack sufficient efficacy for anxiety disorders.
What SHOULD Be Used Instead
For anxiety disorders, the evidence-based treatment hierarchy is:
First-line pharmacotherapy:
- SSRIs: escitalopram, sertraline, fluvoxamine, or paroxetine
- SNRI: venlafaxine
- All carry "weak recommendation/low certainty" but are the standard of care 1
Second-line options:
- Benzodiazepines (alprazolam, bromazepam, clonazepam) for short-term use
- Pregabalin or gabapentin 1
Non-pharmacologic (equally important):
- Cognitive behavioral therapy (CBT) using Clark & Wells or Heimberg models
- Individual therapy preferred over group therapy 1
Critical Caveats About the Conflicting Research
While some older studies (1985-2020) suggested atenolol might reduce anxiety symptoms 2, 3, 4, 5, these have significant limitations:
- Small sample sizes (16-92 patients) 2, 4, 6
- Short duration (2-6 weeks) 4, 6
- Lack of rigorous controls 2
- One study from 1986 actually found atenolol had "unacceptable cardiovascular effects in anxious patients" 6
The 2023 guideline evidence, which synthesized 26 SSRI studies and multiple international guidelines, carries far more weight than these preliminary investigations 1.
FDA-Approved Indications
Atenolol is FDA-approved ONLY for:
- Hypertension (50-100 mg daily)
- Angina pectoris (50-200 mg daily)
- Acute myocardial infarction 7
Anxiety is not an FDA-approved indication, and using it off-label contradicts current guideline recommendations.
The Bottom Line Algorithm
- Do NOT prescribe atenolol for anxiety disorders - it is explicitly deprecated by current guidelines
- Start with an SSRI (escitalopram or sertraline preferred) at standard doses
- Refer for CBT concurrently - individual therapy using evidence-based models
- If SSRI fails or is not tolerated, switch to another SSRI or venlafaxine
- Consider benzodiazepines only for short-term bridging while SSRIs take effect
- Reserve beta-blockers entirely - even propranolol lacks sufficient evidence 8
The historical use of beta-blockers for performance anxiety or situational anxiety does not translate to efficacy for anxiety disorders requiring ongoing treatment, which is what the guidelines address.